Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 18, Issue 5, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ijnp/pyu115
Keywords
Alzheimer's disease; memantine; cholinesterase inhibitors; systematic review; meta-analysis
Ask authors/readers for more resources
Background: We performed an updated meta-analysis of randomized controlled trials of combination therapy with cholinesterase inhibitors and memantine in patients with Alzheimer's disease. Methods: We reviewed cognitive function, activities of daily living, behavioral disturbance, global assessment, discontinuation rate, and individual side effects. Results: Seven studies (total n = 2182) were identified. Combination therapy significantly affected behavioral disturbance scores (standardized mean difference = -0.13), activity of daily living scores (standardized mean difference = -0.10), and global assessment scores (standardized mean difference = -0.15). In addition, cognitive function scores (standardized mean difference = -0.13, P=.06) exhibited favorable trends with combination therapy. The effects of combination therapy were more significant in the moderate-to-severe Alzheimer's disease subgroup in terms of all efficacy outcome scores. The discontinuation rate was similar in both groups, and there were no significant differences in individual side effects. Conclusions: Combination therapy was beneficial for the treatment of moderate-to-severe Alzheimer's disease in terms of cognition, behavioral disturbances, activities of daily living, and global assessment was well tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available